Department of Radiation Oncology, The 74540First Affiliated Hospital of Bengbu Medical College, Bengbu City, Anhui Province, China.
Department of Pathology, The 74540First Affiliated Hospital of Bengbu Medical College, Bengbu City, Anhui Province, China.
J Int Med Res. 2021 May;49(5):3000605211016146. doi: 10.1177/03000605211016146.
Subglottic small cell carcinoma (SSMCC) is a rare type of neoplasm, meaning that laryngeal cancer guidelines in several countries, including the National Comprehensive Cancer Network (NCCN) guidelines, do not include treatment principles for SSMCC. Angiogenesis is an established factor in tumor initiation, growth, and dissemination. Apatinib mesylate, an orally administered drug, is a novel inhibitor of vascular endothelial growth factor receptor-2, a key mediator of angiogenesis, and has been shown to be safe and efficacious in the treatment of certain types of malignant tumors. To the best of our knowledge, there are few reports on the treatment of SSMCC with apatinib combined with concurrent chemoradiotherapy. In the present report of SSMCC in a 64-year-old woman, oral apatinib was given daily at a dose of 250 mg in combination with concurrent chemoradiotherapy; the only toxicities reported were mild leukopenia and finger numbness. Clear and rapid efficacy was observed with the disappearance of the tumor mass. Our findings indicate that apatinib combined with concurrent chemoradiotherapy may be effective in patients with SSMCC, with adverse reactions within the manageable range, thus representing an additional treatment option for this type of malignancy.
声门下小细胞癌（SSMCC）是一种罕见的肿瘤类型，这意味着包括美国国家综合癌症网络（NCCN）指南在内的多个国家的喉癌指南都不包括 SSMCC 的治疗原则。血管生成是肿瘤发生、生长和扩散的既定因素。甲磺酸阿帕替尼是一种口服药物，是一种新型血管内皮生长因子受体-2（VEGFR-2）抑制剂，是血管生成的关键介质，已被证明在治疗某些类型的恶性肿瘤方面是安全有效的。据我们所知，关于阿帕替尼联合同步放化疗治疗 SSMCC 的报道很少。在本报告中，我们对一名 64 岁女性的 SSMCC 进行了治疗，每日口服阿帕替尼 250mg 联合同步放化疗；报告的唯一毒性是轻度白细胞减少和手指麻木。肿瘤体积迅速消失，疗效显著。我们的研究结果表明，阿帕替尼联合同步放化疗可能对 SSMCC 患者有效，不良反应在可控制范围内，因此为这种恶性肿瘤提供了另一种治疗选择。
